Clinical trials: ALS
Amyotrophic Lateral Sclerosis
Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS
This study will assess the efficacy and safety of PTC857 treatment in participants diagnosed with ALS.
- Trial name
- CARDINALS (NCT05349721)
- Testing
- PTC857
- Where
- 55 sites in United States, Argentina and 11 more
- Volunteers
- 336 people
- Sponsor
- PTC Therapeutics
Amyotrophic Lateral Sclerosis, ALS
Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS
Phase 1, open-label study of BHV-0223 in ALS.
- Conditions
- Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease
- Trial name
- NCT03520517
- Testing
- BHV-0223
- Where
- 5 sites in United States
- Volunteers
- 22 people
- Sponsor
- Biohaven Pharmaceuticals, Inc.
Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease
Validation of Biomarkers in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to collect 650 blood and 300 cerebrospinal fluid (CSF) samples from people with amyotrophic lateral sclerosis (ALS), pure lower or upper motor neuron diseases, as well as other neurodegenerative…
- Conditions
- Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, Primary Lateral Sclerosis, Nervous System Diseases
- Trial name
- BIO_ALS-01 (NCT00677768)
- Testing
- No intervention
- Where
- 30 sites in United States, Canada
- Volunteers
- 475 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Amyotrophic Lateral Sclerosis
Correlation Between Intestinal Microflora Metabolites and Amyotrophic Lateral Sclerosis
To verify the correlation between TMAO level and the pathogenesis and progression of ALS
- Trial name
- NCT04948346
- Testing
- diagnosed with ALS
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University Third Hospital
Tetraplegia/Tetraparesis, Quadriplegia
Precise Robotically IMplanted Brain-Computer InterfacE
The PRIME Study is a first-in-human early feasibility study to evaluate the initial clinical safety and device functionality of the Neuralink N1 Implant and R1 Robot device designs in participants with tetraparesis or…
- Conditions
- Tetraplegia/Tetraparesis, Quadriplegia, Cervical Spinal Cord Injury, Amyotrophic Lateral Sclerosis
- Trial name
- PRIME (NCT06429735)
- Testing
- N1 Implant, R1 Robot
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Neuralink Corp
ALS (Amyotrophic Lateral Sclerosis)
Development and Needs Assessment and Efficiency of Smart Communication System for Patients With ALS.
This project aims to develop a smart communication system for patients with amyotrophic lateral sclerosis (ALS), especially for stage 3 and stage 4 (late stage).
- Trial name
- NCT03787420
- Testing
- communication system
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Amyotrophic Lateral Sclerosis
Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.
The study will evaluate the safety, tolerability and therapeutic effects (preliminary efficacy) of injection of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF), as a possible…
- Trial name
- NCT01051882
- Testing
- MSC-NTF cells transplantation (IM), MSC-NTF cells transplantation (IT)
- Where
- Israel
- Volunteers
- 12 people
- Sponsor
- Brainstorm-Cell Therapeutics
Amyotrophic Lateral Sclerosis
Clinical Trial of Glatiramer Acetate in Amyotrophic Lateral Sclerosis (ALS)
Teva is developing 40 mg/ml Glatiramer Acetate (GA) Injection , administered once daily under the skin, for the treatment of ALS.
- Trial name
- NCT00326625
- Testing
- 40 mg glatiramer acetate
- Where
- 7 sites in Belgium, France and 4 more
- Volunteers
- 366 people
- Sponsor
- Teva Pharmaceutical Industries, Ltd.
ALS (Amyotrophic Lateral Sclerosis)
Characterization of Platelet Molecular Profiles in ALS for the Identification of Specific Diagnostic Biomarkers - A Pilot Study
The search for diagnostic biomarkers that can be used routinely is a major challenge to manage Amyotrophic lateral sclerosis (ALS) in order to characterize the pathophysiology and accelerate the management of the disease.
- Trial name
- SLA-PlaQ (NCT07479017)
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Tours
Amyotrophic Lateral Sclerosis
Safety Study of High Doses of Zinc in ALS Patients
The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients.
- Trial name
- NCT01259050
- Testing
- Zinc and Copper
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Phoenix Neurological Associates, LTD
Amyotrophic Lateral Sclerosis
Methodology Study of Novel Outcome Measures to Assess Progression of ALS
The primary objectives of the study are to estimate and rank-order the longitudinal standardized mean changes over 6 months and over 12 months, for a set of outcome measures administered to participants with amyotrophic lateral…
- Trial name
- NCT02611674
- Where
- 21 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Biogen
ALS, Amyotrophic Lateral Sclerosis
Cortex Changes in Real/Imagined Movements in Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to track areas of the brain, via functional magnetic resonance imaging (fMRI), that retain structural and functional integrity throughout the lifespan of people with amyotrophic lateral sclerosis…
- Trial name
- NCT00809224
- Where
- United States
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- University of Michigan
ALS
A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS)
The causes of ALS are largely unknown. However, mitochondrial dysfunction, resulting in impaired energy production, oxidative stress and apoptosis, may play a key role in ALS progression.
- Trial name
- NCT03506425
- Testing
- Triheptanoin
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Richard Bedlack, M.D., Ph.D.
Amyotrophic Lateral Sclerosis (ALS)
Polysomnography-directed Noninvasive Ventilation in Amyotrophic Lateral Sclerosis (ALS)
Use of noninvasive ventilation (NIV, also known colloquially as "Bipap") has been associated in some studies with improvement in pulmonary function, quality of life and survival.
- Trial name
- NCT01363882
- Testing
- Sleep study-guided adjustment of NIV, Standard initiation of NIV
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Columbia University
Frontotemporal Dementia (FTD), GRN Related Frontotemporal Dementia
Predict to Prevent PGRN Disease
Progranulin (GRN or PGRN) mutations are among the most common genetic causes of frontotemporal lobar degeneration (FTLD). With the advent of gene-specific therapeutic interventions, an accurate knowledge of the presymptomatic…
- Trial name
- PREVENT-PGRN (NCT06711510)
- Testing
- Clinical, behavioral and cognitive evaluation, blood sampling, brain MRI
- Sponsor
- Assistance Publique - Hôpitaux de Paris
ALS, ALS (Amyotrophic Lateral Sclerosis)
Systems Biology of Amyotrophic Lateral Sclerosis (ALS)
The goal of this observational study is to identify molecular features in multiple clinical samples and/or the patient environment that are associated with ALS.
- Trial name
- NCT07007390
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Viome
Shortness of Breath, Dyspnea
Neurobiological and Immunological Mechanisms of Dyspnea in ALS (BIOPNEA)
Dyspnea; subjective experience of respiratory discomfort; which produces negative emotional experience, is the most common symptom of patients afflicted with chronic respiratory failure and its treatments are limited.
- Conditions
- Shortness of Breath, Dyspnea, Amyotrophic Lateral Sclerosis
- Trial name
- NCT04332198
- Testing
- biological test
- Volunteers
- 30 people
- Sponsor
- Association pour le Développement et l'Organisation de la Recherche en Pneumologie et sur le Sommeil
Motor Neurone Disease
Assessment of the Effects of Sheffield Support Snood in MND Patients
The aim of this study is to evaluate the effects on MND patients of a new collar specifically designed for people affected by neck weakness: the Sheffield Support Snood.
- Trial name
- NCT02464852
- Testing
- Head movements, Activities of daily living (drinking, washing hand and eating), Sheffield Support Snood
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
COPD, Severe Early-Onset, Ventilatory Failure
Customized Masks in Non-Invasive Mechanical Ventilation
In non-invasive mechanical ventilation (NIMV), the interface is the primary determinant of success, as adherence and quality of therapy mainly depend on it.
- Conditions
- COPD, Severe Early-Onset, Ventilatory Failure, Als, Non Invasive Ventilation
- Trial name
- NCT06215391
- Testing
- 3d printed mask
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Universitario 12 de Octubre
Motor Neuron Disease
Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients
Background: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that selectively affects motor neurons in the brain and spinal cord, leading to bulbar, respiratory, and limb weakness.
- Trial name
- NCT02987413
- Testing
- Autologous Mesenchymal stem cells (MSCs)
- Where
- 2 sites in Brazil
- Volunteers
- 3 people
- Sponsor
- Hospital e Maternidade Dr. Christóvão da Gama